The milestone was specifically connected to one of the several orally available biologics that are the focus of the collaboration.
“We are pleased to have achieved this milestone ahead of schedule,” said Kenneth Carpenter, MediVas' president and CEO. “This is an important accomplishment for MediVas and further demonstrates the capabilities of our polymer delivery platform, particularly for the delivery of biologics.”
MediVas is using its polymer delivery technology to administer drugs through delivery routes that were previously unattainable, such as oral, intranasal, inhaled or subcutaneous injection. This aims to make the administration of the product more convenient.